Utama › COPD › Texas

Kajian klinikal COPD di Texas

25 kajian untuk COPD sedang mencari peserta di lokasi di Texas.

Bandar di Texas

Teks kajian rasmi (Bahasa Inggeris)

A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

Research Site, Abilene
Research Site, Brownsville
Research Site, Dallas
dan 12 lagi

Mengambil pesertaFasa 3

Umur 40 hingga 80 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT06283966

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype

Solace Clinical Research- Site Number : 8400087, Austin
IntraCare- Site Number : 8400034, Dallas
Premier Pulmonary Critical Care and Sleep- Site Number : 8400111, Denison
dan 7 lagi

Mengambil pesertaFasa 3

Umur 40 hingga 80 · Semua jantina · Dikemas kini 1 Okt 2026 · NCT07190222

To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment

Horizon Clinical Research Group., Cypress
Metroplex Pulmonary and Sleep Center, McKinney
DM Clinical Research- Tomball, Tomball

Mengambil pesertaFasa 2

Umur 40 hingga 85 · Semua jantina · Dikemas kini 30 Sep 2026 · NCT07684820

A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis

Copd01 50001, Boerne

Mengambil pesertaFasa 2

Umur 40 hingga 80 · Semua jantina · Dikemas kini 25 Sep 2026 · NCT07725939

A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

Premier Pulmonary Critical Care and Sleep, Denison
Baylor College of Medicine Medical Center, Houston
Prime Clinical Research - Lewisville, Lewisville

Mengambil pesertaFasa 2

Umur 40 hingga 75 · Semua jantina · Dikemas kini 25 Sep 2026 · NCT07759245

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype

Wellness Clinical Research - Allen- Site Number : 8400085, Allen
REX Clinical Trials - Beaumont- Site Number : 8400014, Beaumont
Novel Research - Bellaire- Site Number : 8400116, Bellaire
dan 17 lagi

Mengambil pesertaFasa 3

Umur 40 hingga 80 · Semua jantina · Dikemas kini 22 Sep 2026 · NCT07190209

A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.

REX Clinical Trials - Beaumont- Site Number : 8400011, Beaumont

Mengambil pesertaFasa 4

Umur 40 hingga 85 · Semua jantina · Dikemas kini 22 Sep 2026 · NCT07053423

An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema

University of Texas Southwestern, Dallas

Mengambil peserta

Umur 40 hingga 80 · Semua jantina · Dikemas kini 17 Sep 2026 · NCT06035120

A Study of WIN378 in Participants With Moderate to Severe COPD (Sirius)

WB Contracted Clinical Research Site, McKinney
WB Contracted Clinical Research Site, Waxahachie

Mengambil pesertaFasa 2

Umur 40 hingga 80 · Semua jantina · Dikemas kini 15 Sep 2026 · NCT07646587

A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

Research Site, Boerne
Research Site, Dallas
Research Site, Denison
dan 5 lagi

Mengambil pesertaFasa 2

Umur 40 ke atas · Semua jantina · Dikemas kini 9 Sep 2026 · NCT07082738

Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD

Baylor College of Medicine, Houston

Mengambil pesertaFasa 2

Umur 40 ke atas · Semua jantina · Dikemas kini 4 Sep 2026 · NCT07059091

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)

Research Site, Boerne
Research Site, El Paso
Research Site, Houston
dan 6 lagi

Mengambil pesertaFasa 3

Umur 40 hingga 80 · Semua jantina · Dikemas kini 3 Sep 2026 · NCT06878261

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)

Research Site, Dallas
Research Site, Forney
Research Site, Fort Worth
dan 5 lagi

Mengambil pesertaFasa 3

Umur 40 hingga 80 · Semua jantina · Dikemas kini 3 Sep 2026 · NCT06883305

The Study of Chronic Obstructive Pulmonary Disease (COPD) Participants Treated With Dupilumab (STRIDE) Registry

The Lung & Sleep Institute of North Texas, North Richland Hills

Mengambil pesertaKajian pemerhatian

Umur 40 ke atas · Semua jantina · Dikemas kini 1 Sep 2026 · NCT07612878

A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease

South Texas Medical Research Institute, Inc., DBA TTS Research, Boerne
Ten20 Clinical Research, Carrollton
Horizon Clinical Research Group, Cypress
dan 4 lagi

Mengambil pesertaFasa 2/3

Umur 35 hingga 80 · Semua jantina · Dikemas kini 31 Ogo 2026 · NCT07363694

A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)

GC2501 Study Site 109, Dallas

Mengambil pesertaFasa 3

Umur 18 hingga 80 · Semua jantina · Dikemas kini 11 Ogo 2026 · NCT07555483

STRIVE Post-Market Registry Study

Baylor Scott & White Research Institute, Dallas
University of Texas Southwestern, Dallas
University of Texas Health Science Center at Houston, Houston

Mengambil pesertaKajian pemerhatian

Umur 18 ke atas · Semua jantina · Dikemas kini 3 Ogo 2026 · NCT04302272

eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation

GSK Investigational Site, Dallas
GSK Investigational Site, DeSoto
GSK Investigational Site, Greenville
dan 6 lagi

Mengambil pesertaFasa 3

Umur 40 hingga 75 · Semua jantina · Dikemas kini 28 Jul 2026 · NCT07177339

Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer

Liver Center of Texas, Dallas
Methodist Hospital, Richardson

Mengambil pesertaKajian pemerhatian

Umur 18 ke atas · Semua jantina · Dikemas kini 10 Jul 2026 · NCT05181826

Bronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung - Study 3

Houston Methodist/Primary Critical Care, Houston

Mengambil peserta

Umur 40 hingga 84 · Semua jantina · Dikemas kini 24 Apr 2026 · NCT06891755

Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)

GSK Investigational Site, Austin
GSK Investigational Site, Dallas
GSK Investigational Site, El Paso
dan 5 lagi

Mengambil pesertaFasa 3

Umur 40 hingga 80 · Semua jantina · Dikemas kini 9 Apr 2026 · NCT06961214

Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)

GSK Investigational Site, Corsicana

Mengambil pesertaFasa 3

Umur 40 hingga 80 · Semua jantina · Dikemas kini 8 Okt 2025 · NCT06959095

Interprofessional Pharmacogenomics (IPGx) Registry and Repository

Texas A&M Family Care, Bryan

Mengambil pesertaKajian pemerhatian

Umur 18 ke atas · Semua jantina · Dikemas kini 12 Sep 2025 · NCT06726590

Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening

Horizon Clinical Research Group, Houston
CHRISTUS Trinity Mother Frances Health System, Tyler

Mengambil pesertaKajian pemerhatian

Umur 50 ke atas · Semua jantina · Dikemas kini 5 Ogo 2025 · NCT06122077

myAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home

Respire Research Institute, Houston

Mengambil peserta

Umur 30 ke atas · Semua jantina · Dikemas kini 6 Feb 2025 · NCT05204888

Daripada ClinicalTrials.gov, data diperoleh pada 4 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.